Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | hypothetical protein | 0.0138 | 0.5 | 0.5 |
Schistosoma mansoni | family S9 non-peptidase homologue (S09 family) | 0.0138 | 0.5 | 0.5 |
Loa Loa (eye worm) | acetylcholinesterase 1 | 0.0138 | 0.5 | 0.5 |
Echinococcus multilocularis | acetylcholinesterase | 0.0138 | 0.5 | 0.5 |
Echinococcus granulosus | acetylcholinesterase | 0.0138 | 0.5 | 0.5 |
Echinococcus granulosus | acetylcholinesterase | 0.0138 | 0.5 | 0.5 |
Loa Loa (eye worm) | carboxylesterase | 0.0138 | 0.5 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0138 | 0.5 | 0.5 |
Echinococcus granulosus | carboxylesterase 5A | 0.0138 | 0.5 | 0.5 |
Echinococcus multilocularis | acetylcholinesterase | 0.0138 | 0.5 | 0.5 |
Brugia malayi | Carboxylesterase family protein | 0.0138 | 0.5 | 0.5 |
Echinococcus multilocularis | carboxylesterase 5A | 0.0138 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 22.3872 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID540262] | ChEMBL. | No reference |
Potency (functional) | 25.1189 uM | PubChem BioAssay. qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 39.8107 uM | PubChem BioAssay. qHTS Assay to Find Inhibitors of Pin1. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 125.8925 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID540273] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.